Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin’s lymphoma and characterization of the loss of the target antigen
Based on specificity, efficacy, and loss of the target antigen, CARLY3 represents a potential novel CAR treatment for NHL.
Authors
- Juana Serrano‐López (ORCID: https://orcid.org/0000-0001-8140-9040)
- Pilar Llamas (ORCID: https://orcid.org/0000-0002-8552-3219)
- Laura Solán (ORCID: https://orcid.org/0000-0001-8949-8762)
- Jennifer Borregón
- Manel Juan (ORCID: https://orcid.org/0000-0002-3064-1648)
- Víctor Sandá (ORCID: https://orcid.org/0009-0005-3730-6825)
- Beatriz Martín-Antonio (ORCID: https://orcid.org/0000-0003-0612-2693)
- Pablo Engel (ORCID: https://orcid.org/0000-0001-8410-252X)
- Narcís Fernández‐Fuentes (ORCID: https://orcid.org/0000-0002-6421-1080)
- Esperanza Esquinas
- Alvaro Moreno-Sanz
- Damian Stodulski-Ciesla
- Virginia Peña-Blanque
- Javier Fernández‐Calles
Institutions
- Instituto de Salud Carlos III (ES)
- Josep Carreras Leukaemia Research Institute (ES)
- CARSA (Spain) (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universidad Autónoma de Madrid (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-009485
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Instituto de Salud Carlos III